[go: up one dir, main page]

RU99127433A - ERGOLINE DERIVATIVES AND THEIR APPLICATION AS ANTAGONISTS OF SOMATOSTATIN RECEPTORS - Google Patents

ERGOLINE DERIVATIVES AND THEIR APPLICATION AS ANTAGONISTS OF SOMATOSTATIN RECEPTORS

Info

Publication number
RU99127433A
RU99127433A RU99127433/04A RU99127433A RU99127433A RU 99127433 A RU99127433 A RU 99127433A RU 99127433/04 A RU99127433/04 A RU 99127433/04A RU 99127433 A RU99127433 A RU 99127433A RU 99127433 A RU99127433 A RU 99127433A
Authority
RU
Russia
Prior art keywords
formula
free base
denotes
compound
pharmaceutically acceptable
Prior art date
Application number
RU99127433/04A
Other languages
Russian (ru)
Other versions
RU2191776C2 (en
Inventor
Пауль ПФЭФФЛИ
Петер Нойманн
Роберт Свобода
Петер ШТЮТЦ
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9711043.1A external-priority patent/GB9711043D0/en
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU99127433A publication Critical patent/RU99127433A/en
Application granted granted Critical
Publication of RU2191776C2 publication Critical patent/RU2191776C2/en

Links

Claims (10)

1. Соединение формулы I
Figure 00000001

где R1 обозначает водород, C1-C4алкил или группу формулы
Figure 00000002

в которой n равно 1-4 и R7 обозначает фтор, хлор, гидрокси, C1-C4алкил или C1-C4алкокси;
R2 обозначает водород, хлор, бром, йод, С1-C4алкил или C1-C4алкилтио,
R3 обозначает водород или C1-C4алкил;
R4 обозначает (I) группу формулы
Figure 00000003

или
Figure 00000004

где R8 обозначает фтор, хлор, нитро или пиано, и R11 обозначает C1-C4алкил или С2-С8алкенил, или (II) группу формулы
Figure 00000005

или
Figure 00000006

где радикалы Х независимо друг от друга обозначают О или S, и R5 и R6 каждый обозначает водород или вместе образуют дополнительную связь
между двумя атомами углерода, к которым они присоединены, в форме свободного основания или в форме кислотно-аддитивной соли.1. The compound of formula I
Figure 00000001

where R 1 denotes hydrogen, C 1 -C 4 alkyl or a group of the formula
Figure 00000002

in which n is 1-4 and R 7 denotes fluorine, chlorine, hydroxy, C 1 -C 4 alkyl or C 1 -C 4 alkoxy;
R 2 denotes hydrogen, chlorine, bromine, iodine, C 1 -C 4 alkyl or C 1 -C 4 alkylthio,
R 3 is hydrogen or C 1 -C 4 alkyl;
R 4 means (I) a group of the formula
Figure 00000003

or
Figure 00000004

where R 8 denotes fluorine, chlorine, nitro or piano, and R 11 denotes C 1 -C 4 alkyl or C 2 -C 8 alkenyl, or (II) a group of the formula
Figure 00000005

or
Figure 00000006

where the radicals X independently of one another denote O or S, and R 5 and R 6 each denotes hydrogen or together form an additional bond
between the two carbon atoms to which they are attached, in the form of a free base or in the form of an acid addition salt. 2. Соединение формулы I по п.1, в котором R4 обозначает группу формулы (г), в форме свободного основания или в форме кислотно-аддитивной соли.2. The compound of formula I according to claim 1, in which R 4 denotes a group of formula (g), in the form of a free base or in the form of an acid addition salt. 3. Соединение формулы I по п.1, в котором R4 обозначает группу формулы (д), в форме свободного основания или в форме кислотно-аддитивной соли.3. The compound of formula I according to claim 1, in which R 4 denotes a group of formula (d), in the form of a free base or in the form of an acid addition salt. 4. Способ получения соединения формулы I по п.1 или его соли, который включает взаимодействие соединения формулы II
Figure 00000007

где R1, R2, R3, R5 и R6 имеют значения, указанные в п.1, а М обозначает Н или щелочной металл, с соединением формулы III
Figure 00000008

где R4 имеет значения, указанные в п.1, и восстановление полученного таким путем соединения формулы I в форме свободного основания или в форме кислотно-аддитивной соли.4. The method of obtaining the compounds of formula I according to claim 1 or its salt, which includes the interaction of the compounds of formula II
Figure 00000007

where R 1 , R 2 , R 3 , R 5 and R 6 have the meanings indicated in paragraph 1, and M denotes H or an alkali metal, with a compound of formula III
Figure 00000008

where R 4 has the meanings indicated in claim 1 and the reduction of the compound of formula I thus obtained in the form of the free base or in the form of an acid addition salt. 5. Соединение по любому из пп.1-3 в форме свободного основания или в форме фармацевтически приемлемой кислотно-аддитивной соли, предназначенное для применения в качестве лекарственного средства. 5. The compound according to any one of claims 1 to 3 in the form of a free base or in the form of a pharmaceutically acceptable acid additive salt, intended for use as a medicine. 6. Соединение по любому из пп.1-3 в форме свободного основания или в форме фармацевтически приемлемой кислотно-аддитивной соли, предназначенное для лечения депрессии, состояния тревоги, биполярных нарушений и дефицита внимания и нарушений, связанных с гиперактивностью (ДВНГ). 6. The compound according to any one of claims 1 to 3 in the form of a free base or in the form of a pharmaceutically acceptable acid additive salt, intended for the treatment of depression, anxiety, bipolar disorders and attention deficit disorders and disorders associated with hyperactivity (DVNG). 7. Фармацевтическая композиция, содержащая соединение по любому из пп. 1-3 в форме свободного основания или в форме фармацевтически приемлемой кислотно-аддитивной соли в сочетании с фармацевтическим носителем или растворителем. 7. A pharmaceutical composition comprising a compound according to any one of claims. 1-3 in free base form or in the form of a pharmaceutically acceptable acid addition salt in combination with a pharmaceutical carrier or diluent. 8. Применение соединения по любому из пп.1-3 в форме свободного основания или в форме фармацевтически приемлемой кислотно-аддитивной соли в качестве лекарственного средства, предназначенного для лечения депрессии, состояния тревоги, биполярных нарушений и ДВНГ. 8. The use of compounds according to any one of claims 1 to 3 in the form of a free base or in the form of a pharmaceutically acceptable acid additive salt as a drug intended for the treatment of depression, anxiety, bipolar disorders and DVNG. 9. Применение соединения по любому из пп.1-3 в форме свободного основания или в форме фармацевтически приемлемой кислотно-аддитивной соли для приготовления лекарственного средства, предназначенного для лечения депрессии, состояния тревоги, биполярных нарушений и ДВНГ. 9. The use of compounds according to any one of claims 1 to 3 in the form of a free base or in the form of a pharmaceutically acceptable acid additive salt for the preparation of a medicinal product intended for the treatment of depression, anxiety, bipolar disorders and DVNG. 10. Способ лечения депрессии, состояния тревоги, биполярных нарушений и ДВНГ у пациента, нуждающегося в таком лечении, включающий введение пациенту терапевтически эффективного количества соединения по любому из пп.1-3 в форме свободного основания или в форме фармацевтически приемлемой кислотно-аддитивной соли. 10. A method of treating depression, anxiety, bipolar disorder and DVNG in a patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of a compound according to any one of claims 1 to 3 in the form of a free base or in the form of a pharmaceutically acceptable acid addition salt.
RU99127433/04A 1997-05-29 1998-05-27 Ergoline derivatives, method of their synthesis, pharmaceutical composition RU2191776C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9711043.1 1997-05-29
GBGB9711043.1A GB9711043D0 (en) 1997-05-29 1997-05-29 Organic compounds

Publications (2)

Publication Number Publication Date
RU99127433A true RU99127433A (en) 2001-09-10
RU2191776C2 RU2191776C2 (en) 2002-10-27

Family

ID=10813201

Family Applications (1)

Application Number Title Priority Date Filing Date
RU99127433/04A RU2191776C2 (en) 1997-05-29 1998-05-27 Ergoline derivatives, method of their synthesis, pharmaceutical composition

Country Status (24)

Country Link
US (1) US6221870B1 (en)
EP (1) EP0986558A2 (en)
JP (1) JP2001527580A (en)
KR (1) KR20010013103A (en)
CN (1) CN1259946A (en)
AR (1) AR012870A1 (en)
AU (1) AU727841B2 (en)
BR (1) BR9809491A (en)
CA (1) CA2288810A1 (en)
CO (1) CO4950561A1 (en)
CZ (1) CZ289466B6 (en)
GB (1) GB9711043D0 (en)
HU (1) HUP0002311A3 (en)
ID (1) ID22916A (en)
IL (1) IL132571A0 (en)
NO (1) NO995482L (en)
NZ (1) NZ500386A (en)
PE (1) PE74899A1 (en)
PL (1) PL336502A1 (en)
RU (1) RU2191776C2 (en)
SK (1) SK160899A3 (en)
TR (1) TR199902848T2 (en)
WO (1) WO1998054183A2 (en)
ZA (1) ZA984560B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2329273C2 (en) * 2003-04-11 2008-07-20 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик С.А.С. Chimeric equivalents of ligans of somatostatin and dopermine receptors, pharmaceutical compositions based on them and modalties of somatostatin and/dopermine receptors

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10053397A1 (en) * 2000-10-20 2002-05-02 Schering Ag Use of a dopaminergic active ingredient for the treatment of dopaminerg treatable diseases
DE10066158B4 (en) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Use of a transdermal therapeutic system for the treatment of Restless Legs Syndrome
DE10341317B4 (en) * 2003-09-03 2008-10-23 Axxonis Pharma Ag Transdermal therapeutic system (TTS) for administration of ergoline compounds except pergolide
US20070243240A9 (en) * 2000-08-24 2007-10-18 Fred Windt-Hanke Transdermal therapeutic system
CN1514843A (en) * 2001-06-08 2004-07-21 �о���Ӧ�ÿ�ѧЭ��ɷ����޹�˾ somatostatin-dopamine chimeric analog
FI20031454A0 (en) 2003-10-06 2003-10-06 Juvantia Pharma Ltd Oy Selective somatostatin receptor 1 and / or 4 agonists and antagonists
KR101000923B1 (en) * 2004-01-08 2010-12-13 삼성전자주식회사 Apparatus and method for setting a macro of a remote controller
CA2609161A1 (en) * 2005-05-18 2006-11-23 Siegfried Wurster Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4
JP2007067096A (en) * 2005-08-30 2007-03-15 Fujitsu Ltd Semiconductor device
SG181896A1 (en) * 2009-12-23 2012-07-30 Map Pharmaceuticals Inc Novel ergoline analogs
CN103827113A (en) 2011-06-23 2014-05-28 Map药物公司 Novel fluoroergoline analogs
EP2793580A4 (en) 2011-12-19 2015-05-20 Map Pharmaceuticals Inc Novel iso-ergoline derivatives
US8946420B2 (en) 2011-12-21 2015-02-03 Map Pharmaceuticals, Inc. Neuromodulatory compounds
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
EP2914276A4 (en) 2012-11-01 2016-07-13 Ipsen Pharma Sas Somatostatin analogs and dimers thereof
TWI523863B (en) 2012-11-01 2016-03-01 艾普森藥品公司 Somatostatin-dopamine chimeric analogs
CA2974113A1 (en) 2015-01-20 2016-07-28 Xoc Pharmaceuticals, Inc. Isoergoline compounds and uses thereof
BR112017015487A2 (en) 2015-01-20 2018-01-30 Xoc Pharmaceuticals Inc COMPOUND; COMPOSITION; METHOD OF TREATMENT AND / OR PREVENTION OF MIGRAINE, ALS, ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, EXTRAPYRIMIDAL DISORDERS, DEPRESSION, NAUSEA, AEMESIS, SYNDROME OF THE WASTE LEGS, INSOMENESS, HYGERNESS, AGING , ANXIETY, DRUG DEPENDENCIES, DYSTONIA, PARASSONIA OR HYPERLACTINEMIA IN AN INDIVIDUAL; AGONIZATION METHODS OF D2, 5-HT1D, 5-HT1A AND 5-HT2C RECEPTORS, IN AN INDIVIDUAL; ANTAGONIZATION METHOD OF THE D3 RECEPTOR IN AN INDIVIDUAL; METHODS OF SELECTIVE AGONIZATION OF RECEPTORS 5 -HT1D, AND 5-HT2C, METHOD OF PROVIDING FUNCTIONAL ANTAGONIST ACTIVITY IN RECEPTOR 5 -HT2B OR IN RECEIVER 5-HT7, OR IN BOTH, IN AN INDIVIDUAL; METHOD OF PROVIDING FUNCTIONAL ANTAGONIST ACTIVITY IN ADRENERGIC RECEPTORS IN AN INDIVIDUAL
CA3064274A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine
JP7099717B2 (en) 2019-09-30 2022-07-12 株式会社理研バイオ Somatostatin receptor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1695682U (en) * 1955-01-13 1955-03-31 Otto Berning & Co ADJUSTABLE COLLAR STICK.
US3592816A (en) 1966-02-08 1971-07-13 Sandoz Ltd N-substituted piperazides of lysergic acid
CH475252A (en) * 1966-02-08 1969-07-15 Sandoz Ag Process for the production of new lysergic acid derivatives
GB1188197A (en) 1967-10-11 1970-04-15 Sandoz Ltd Lysergic Acid Derivatives
NL6818658A (en) * 1968-01-18 1969-07-22
GB1580448A (en) * 1976-12-06 1980-12-03 Farmaceutici Italia 8 -acetyl-6-methyl-ergoline i derivatives
GB8501078D0 (en) * 1985-01-16 1985-02-20 Erba Farmitalia Piperazin-1-yl-ergo-line derivatives
TW357143B (en) 1995-07-07 1999-05-01 Novartis Ag Benzo[g]quinoline derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2329273C2 (en) * 2003-04-11 2008-07-20 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик С.А.С. Chimeric equivalents of ligans of somatostatin and dopermine receptors, pharmaceutical compositions based on them and modalties of somatostatin and/dopermine receptors

Similar Documents

Publication Publication Date Title
RU99127433A (en) ERGOLINE DERIVATIVES AND THEIR APPLICATION AS ANTAGONISTS OF SOMATOSTATIN RECEPTORS
RU2324684C2 (en) Pyrimidine derivatives
RU2201224C2 (en) Compounds active in novel site on receptor-regulating calcium channels and used for treatment of neurological disturbances and diseases
ATE219363T1 (en) SOLUBLE PRODRUGS OF PACLITAXEL
EP1619192A3 (en) Aryl fused azapolycyclic compounds
JP2004514663A5 (en)
EA200000682A1 (en) NEW ACYLGUANIDINE DERIVATIVES AS AN INHIBITORS OF BONE TISSUE RESORPTION AND VITRONECTIN RECEPTORS ANTAGONISTS
RU96117041A (en) APPLICATION OF DERIVATIVES OF 2-HYDROXY-5-PHYNYLESE-BENZOIC ACID AS CHEMIOPROPHYLACTIC AND CHEMOTHERAPEUTIC AGENTS FOR CANCER OF THE COLUMNIA
RU2001133004A (en) The use of selective alpha1b-adrenergic receptor antagonists to improve sexual dysfunction
MA28742B1 (en) PYRIDO-PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
RU2003133924A (en) DEUTERED 3-PIPERIDINOETHYLPHENYLKETONES, AND ALSO MEDICINES CONTAINING THESE COMPOUNDS
DE69200045D1 (en) Thiazolopyrimidine derivatives as angiotensin II receptor antagonists: process for their preparation and pharmaceutical compositions containing them.
RU2218334C2 (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine-10-ol's and pharmaceutical composition based on thereof
RU99110941A (en) NEW DERIVATIVES 1,7,7-TRIMETHYL-BICYCLO [2,2,1] GEPTANA
RU94039545A (en) New adenosine derivatives, methods of their synthesis, pharmaceutical compositions based on thereof, methods of preparing pharmaceutical compositions and their use
JP2005513049A5 (en)
RU2007128080A (en) Pyrrolidinium derivatives as muscarinic receptors of the Ministry of Health
KR920016418A (en) NMDA antagonist
RU2005138143A (en) MITYLINDOLES AND METHYLPYRROLOPYRIDINES AS L-1-ADRENERGIC AGONISTS
DE69217613D1 (en) Bicyclic derivatives containing nitrogen, processes for their preparation and pharmaceutical preparations containing them
RU2000111500A (en) PHARMACEUTICAL COMBINED DRUGS
ATE169635T1 (en) THERAPEUTIC COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH GLUTATHIONE DEFICIENCY, PRODUCTION PROCESS AND PHARMACEUTICAL COMPOSITIONS CONTAINED THEREOF
RU2002132883A (en) NEW POLYCYCLIC INDANYLIMIDAZOLE POSSESSING ALPHA2 ADRENERGIC ACTIVITY
MA27492A1 (en) NOVEL ANTAGONIST DERIVATIVES OF THE VITRONECTIN RECEPTOR, THEIR PREPARATION PROCESS, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
HUP0203790A2 (en) Use of compositions containing 6-methoxy-2-naphthylacetic acid prodrugs for treating inflammation